| Effect | None |
| Trial Design | Double blind |
| Trial Length | 1-6 months |
| Number of Subjects | 137 |
| Sex | Both Genders |
| Age Range | 45-64 |
| Body Types | Obese |
Supplementation of 1mg chromium (in the form of chromium picolinate) in two divided doses daily for 24 weeks in type II diabetics noted that while there was a trend to increase insulin sensitivity, this was not statistically significant and only 46% of persons were considered responders.
No other changes were noted in diet, glucose metabolism, and the response to chromium was more associated with baseline insulin resistance rather than the kinetics of chromium after ingestion.
